Northwire Canada EditionSunday, July 12, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%

Healthcare

Page 27
  1. Apr 29, 2026 · 08:42 · OTC · Neutral

    Ocumetics Raises $1.5M to Fuel Clinical Progress Amidst Dilution and Debt Overhang

    Ocumetics Announces Offering of Units

    01
  2. Apr 29, 2026 · 08:01 · IZO · Routine +

    Izotropic Africa Launches Operations Amidst Debt Settlement and JV Delays

    Izotropic Africa Launches Operations in Casablanca

    02
  3. Apr 29, 2026 · 08:00 · PINK · Routine +

    Perimeter Showcases FDA-Approved Claire System at ASBrS 2026

    Perimeter Showcases Claire(TM) for Intraoperative Breast Cancer Margin Assessment at ASBrS 2026

    03
  4. Apr 29, 2026 · 07:06 · MBIO · Routine +

    MindBio Patents Voice AI Intoxication Tech Amidst Clinical Pivot; Stock Consolidates Near Support

    MindBio Files Patent Applications in 15 World Firsts

    04
  5. Apr 29, 2026 · 06:58 · BLCO · Routine +

    Bausch + Lomb Beats Q1 Estimates but Debt Overhang Persists Amid Turnaround Execution

    Bausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive Outlook

    05
  6. Apr 28, 2026 · 18:00 · SKNY · Neutral

    LIR Life Sciences Advances Transdermal Platform Amidst Stock Decline; No Clinical Catalysts Yet

    LIR Life Sciences Launches Ex Vivo Animal Study to Evaluate Protamine Enhanced Transdermal Transport of Larger Format Therapeutic Molecules

    06
  7. Apr 28, 2026 · 18:00 · ONCO · Routine +

    Manufacturing Milestone Achieved Amidst Severe Dilution and Price Collapse

    Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

    07
  8. Apr 28, 2026 · 16:30 · BIOV · Routine −

    BioVaxys Shares Plunge as Filing Default Extends Amidst Clinical Progress

    BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

    08
  9. Apr 28, 2026 · 08:15 · PINK · Routine +

    CEO Insider Commitment Validates FDA Milestone But Dilution Concerns Persist Amidst Consolidation

    Perimeter Medical Imaging AI Closes First Tranche of Non-Brokered Private Placement

    09
  10. Apr 28, 2026 · 08:00 · VPT · Routine +

    Ventripoint Advances China Entry Amidst Persistent Dilution Concerns

    Ventripoint's VMS+ (TM) 4.0 Submitted for Regulatory Approval in China by Lishman Global Inc.

    10
  11. Apr 28, 2026 · 07:30 · HELP · Routine +

    Leadership Transition and Recruitment Partnership

    Helus Pharma Partners with TARA Mind to Advance Veteran Mental Health

    11
  12. Apr 28, 2026 · 07:27 · CRDL · Routine +

    Cardiol Therapeutics Expands Pivotal Trial Network as Enrollment Hits 75%

    Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program

    12
  13. Apr 28, 2026 · 03:05 · BNXT · Routine +

    BioNxt Expands Platform into Psychedelics Amidst Clinical Readiness Milestones

    BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

    13
  14. Apr 27, 2026 · 19:00 · 4875 · Routine +

    MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

    New Peer-Reviewed Study Reveals Actionable Immune-Microenvironment Target in Brain Metastasis; Medicinova Advances Clinical Translation

    14
← Newer Older →